Fonterra’s NZMP Category Marketing Manager for Paediatrics, Angela Rowan says the finalist announcement is exciting, reinforcing the importance NZMP places on clinical studies to back up innovation,
“We are very proud that MFGM Lipid 100 was shortlisted as a finalist, which we believe is due to strong, scientific and clinical studies on the ingredient, supporting brain development and cognition.”
Winners are announced in Singapore on Monday 10 September.
Some of the impressive science behind MFGM Lipid 100:
- Two clinical studies were carried out in China to investigate the effects of providing additional MFGM (milk fat globule membrane) gangliosides (GA) and phospholipids (PL) during pregnancy and in infancy.
- Both studies looked at the effects of providing MFGM to support cognitive development.
- Preliminary findings on supplementation with MFGM in healthy infants in the first 12 months of life showed statistically significant improvements in cognitive development.
Fonterra’s consumer brand Anmum™ is the first to take this innovative ingredient to market used in maternal and paediatric products, Anmum™ with Nuelipid™.
Breast milk is the ideal source of nutrition for infants. It contains everything a baby needs up to 6-months-of-age to grow and develop in a healthy way and gives children the very best start in life. Breast milk substitutes are recognised by the World Health Organisation as the only safe and nutritious alternative to breast milk for infants whose mothers cannot, or choose not to, breastfeed.